
Jazz Pharmaceuticals Announces Zepzelca® (Lurbinectedin) And Atezolizumab (Tecentriq®) Combination Significantly ...
(MENAFN- PR Newswire) First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 …